Patient characteristics at study entry
Characteristics . | Alternating . | Concurrent . |
|---|---|---|
| Median age, y (range) | 46 (21-65) | 41 (19-63) |
| Sex, no. (%) | ||
| Male | 25 (53) | 23 (51) |
| Female | 22 (47) | 22 (49) |
| Subtype of ALL, no. (%) | ||
| c-ALL | 33 (70) | 28 (62) |
| Pre-B-ALL | 10 (21) | 14 (31) |
| NA | 0 (0) | 3 (7) |
| Lymphoid blast crisis | 4 (9) | 0 (0) |
| BCR-ABL transcripts, no. (%) | ||
| P210BCR-ABL | 20 (43) | 12 (27) |
| P190BCR-ABL | 26 (55) | 31 (69) |
| NA | 1 (2) | 2 (4) |
| Disease status at study start, no. (%)* | ||
| CR1 | 44 (94) | 24 (54) |
| PR | 3 (6) | 10 (22) |
| No response | 0 (0) | 9 (20) |
| NA | 0 (0) | 2 (4) |
Characteristics . | Alternating . | Concurrent . |
|---|---|---|
| Median age, y (range) | 46 (21-65) | 41 (19-63) |
| Sex, no. (%) | ||
| Male | 25 (53) | 23 (51) |
| Female | 22 (47) | 22 (49) |
| Subtype of ALL, no. (%) | ||
| c-ALL | 33 (70) | 28 (62) |
| Pre-B-ALL | 10 (21) | 14 (31) |
| NA | 0 (0) | 3 (7) |
| Lymphoid blast crisis | 4 (9) | 0 (0) |
| BCR-ABL transcripts, no. (%) | ||
| P210BCR-ABL | 20 (43) | 12 (27) |
| P190BCR-ABL | 26 (55) | 31 (69) |
| NA | 1 (2) | 2 (4) |
| Disease status at study start, no. (%)* | ||
| CR1 | 44 (94) | 24 (54) |
| PR | 3 (6) | 10 (22) |
| No response | 0 (0) | 9 (20) |
| NA | 0 (0) | 2 (4) |
For patients on the alternating schedule, n = 47; for patients on the concurrent schedule, n = 45.
NA indicates not available; CR1, first complete remission; and PR, partial remission
With the alternating schedule, patients were enrolled after INDII if they had achieved a remission in response to induction chemotherapy; with the concurrent administration schedule, patients already entered the study after INDI, irrespective of their response to chemotherapy